Verseon Corporation Verseon presents low bleed PROACs at ISC 2019
11 Février 2019 - 8:00AM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
11 February 2019
February 11, 2019
Verseon Corporation
("Verseon" or the "Company")
Verseon Presents PRecision Oral Anticoagulants (PROACs) with Low
Bleeding at International Stroke Conference 2019
FREMONT, Calif.-Verseon, the clinical-stage pharmaceutical
company developing disruptive life-science technology to advance
global health, presented its PROACs (PRecision Oral AntiCoagulants)
at last week's International Stroke Conference in Honolulu, HI. Due
to their novel combination of efficacy, low bleeding, and sparing
of platelet function that was observed in preclinical testing,
PROACs could become the first anticoagulants suitable for long-term
co-administration with antiplatelet drugs for patients with
coronary artery disease.
Millions of patients worldwide could benefit from safe,
long-term therapy combining an oral anticoagulant with one or more
antiplatelet drugs (i.e. aspirin, Plavix(TM) ) to prevent stroke or
heart attack. With current anticoagulants, however, such
combination treatment is generally limited to 12 months because of
an increased risk of major bleeding. Verseon's PROACs have
demonstrated significantly reduced bleeding in preclinical studies,
which could make them uniquely suited for these patients.
In contrast to conventional pharma companies that typically rely
on a single compound per program, Verseon is using its
computer-driven drug development platform to generate multiple
chemically distinct drug candidates for each disease area. As a
result, the company is currently conducting a phase 1 trial on the
lead PROAC, VE-1902, and expects to also advance a second PROAC,
VE-2851, into clinical trials.
At the International Stroke Conference, Dr. Mohan Sivaraja,
Verseon's Director of In Vitro Discovery Biology, presented the
preclinical profiles of both clinical candidates. Dr. Sivaraja
presented preclinical efficacy models showing that PROACs inhibit
clot formation as effectively as currently available therapies,
along with multiple safety studies showing less bleeding and a
sparing of platelet function-features that distinguish PROACs from
the currently available NOACs and make them promising therapeutic
candidates.
"Our preclinical studies have shown that PROACs have a distinct
pharmacological profile that sets them apart from NOACs," said Dr.
Sivaraja. "PROACs inhibit clots without disrupting platelet
function. This explains their lower bleeding in preclinical models
and makes them promising alternatives for a large number of
patients who need long-term combination therapy with antiplatelet
medication. We are excited to bring these compounds one step closer
to patients."
About the phase I trial for VE-1902
"A Study of Safety, Pharmacokinetics, and Pharmacodynamics of
Single and Multiple Ascending Oral Doses of VE-01902 in Healthy
Volunteers"
The phase I trial for Verseon's first PROAC, VE-1902, (trial ID
ACTRN12618001509257) is a single-center, double-blinded,
randomized, placebo-controlled study of the safety, tolerability,
and composite hemostatic profile in healthy volunteers. Secondary
endpoints will assess pharmacokinetic and pharmacodynamic profiles
of VE-1902. The study will include once-a-day oral dosing in two
stages: a single ascending dose stage with a food effect cohort and
a multiple ascending dose stage with 7-day repeat dosing. The trial
is being conducted at Nucleus Network in Melbourne, Australia.
About Verseon's PROACs
Verseon's PRrecision Oral AntiCoagulants (PROACs) have shown
excellent efficacy in multiple preclinical studies without
disruption of platelet function. This unique feature could explain
the low bleeding of the PROACs observed in preclinical testing,
making PROACs excellent candidates for use in long-term combination
anticoagulant-antiplatelet therapy. Lead PROAC VE--1902, which is
currently in a phase I clinical trial, was well-tolerated in
regulatory toxicity studies and demonstrated low renal clearance, a
desirable property for patients with impaired kidney function.
Verseon is also advancing a second PROAC, VE-2851, for clinical
trials.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is developing
disruptive life-science technology to advance global health. The
clinical-stage company is using its proprietary, computational drug
discovery platform paired with a comprehensive in-house chemistry
and biology workflow to build a growing drug development pipeline.
The company is applying its platform to a growing drug pipeline and
currently has four active drug programs in the areas of
anticoagulation, diabetic macular edema, hereditary angioedema, and
oncology.
- Ends -
For further information, please contact
Verseon Corporation www.verseon.com
Sebastian Wykeham / Tina Schlafly +1 510 225 9000
Arden Partners (NOMAD and Joint Broker)
+44 (0) 20 7614
Ruari McGirr / Ciaran Walsh 5900
Cantor Fitzgerald Europe (Joint Broker)
+44 (0) 20 7894
Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers)
+44 (0) 20 7466
Henry Harrison-Topham / Jamie Hooper 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737 821
Simon Vane Percy 890
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALIFIIFRILLIA
(END) Dow Jones Newswires
February 11, 2019 02:00 ET (07:00 GMT)
Verseon (LSE:VSN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Verseon (LSE:VSN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024